- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04024735
Mechanisms of COPD Exacerbation Recurrence
Chronic obstructive pulmonary disease (COPD) is a common smoking-related lung disease. Patients with COPD are at increased risk of readmission to hospitals within the following 30 days. Hospital readmissions of COPD contribute to clinical and economic burden on society. Understanding why some COPD patients are readmitted remains a key area of unmet need.
To our knowledge, no previous study has fully investigated both the social and clinical risk factors associated with these types of patients. The investigators want to prospectively and comprehensively explore the possible causes, whether clinical or social factors, that cause rehospitalisation. The investigators will be collecting demographic and clinical information including daily physical activity level, lung function, blood and sputum samples. These measurements will be collected at patient admission, discharge and at follow-up of 30 and 90 days. This process could lead to a better understanding of the reasons which prevent early hospital readmission for those patients.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, NW3 2PF
- Recruiting
- Royal Free Hospital NHS
-
Contact:
- Jaber S Alqahtani, MSc
- Phone Number: +447846713703
- Email: jaber.alqahtani.18@ucl.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who have a primary diagnosis of COPD
- Patients admitted to hospital with an exacerbation.
Exclusion Criteria:
- Patients in whom an initial diagnosis of an AECOPD is revised to an alternative at a later phase of the study.
- Patients who have a predominant history of asthma
- Patients with a confirmed active malignancy
- Patients who have a predominant history of bronchiectasis.
- Cognitive impairment patients with a Mental Test Score (MTS) of 6 or less.
- Inability to give informed consent to take part in the study
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary outcome is the factors that determine readmission to hospital within 30 and 90 days post discharge.
Time Frame: 30 and 90 days
|
30 and 90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Readmission rate at 30 days and at 3 months
Time Frame: 30 and 90 days
|
30 and 90 days
|
|
Prevalence of comorbidities between those who are and are not readmitted within 30 and 90 days.
Time Frame: 30 and 90 days
|
30 and 90 days
|
|
Changes in admission-to-discharge in within breath reactance (∆Xrs5Hz) between patients who are and are not readmitted to the hospital within 30 and 90 days.
Time Frame: 30 and 90 days
|
30 and 90 days
|
|
Change in the modified Medical Research Council scale (mMRC) at admission, discharge and after 30 days follow-up or at readmission.
Time Frame: 30 and 90 days
|
It is used to scale breathlessness, ranges from 0 to 4 which higher values represent a worse outcome.
|
30 and 90 days
|
Change in quality of life by measuring COPD assessment test (CAT) at admission, discharge and after 30 days follow-up or at readmission.
Time Frame: 30 and 90 days
|
It is used to scale patient's quality of life.
Range of CAT scores from 0-40 which higher scores denote a more severe impact of COPD on a patient's life.
|
30 and 90 days
|
Change in Hospital Anxiety and Depression Scale (HADS) at admission, discharge and after 30 days follow-up or at readmission.
Time Frame: 30 and 90 days
|
It is used to scale patient's quality of life.
The questionnaire comprises seven questions for anxiety and seven questions for depression.
Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
The higher score indicates a worse outcome.
|
30 and 90 days
|
Prevalence of frailty between those who are and are not readmitted to the hospital within 30 and 90 days.
Time Frame: 30 and 90 days
|
30 and 90 days
|
|
Change in physical activity level (daily steps) following the discharge between patients who are and are not readmitted.
Time Frame: 30 days
|
Step counter (pedometer) will be given to wear throughout the 30 days period to measure the daily steps.
|
30 days
|
Changes in admission-to-discharge peak inspiration flow rate (PIFR) between patients who are and are not readmitted.
Time Frame: 30 and 90 days
|
The In-Check DIAL device will be used which is capable of measuring inspiratory flow rates between 0 and 120 L/min.
Optimal PIFR, more than 60 L/min; and sub-optimal PIFR, 60 L/min or less).
|
30 and 90 days
|
Change in white cell count (WCC) blood biomarkers
Time Frame: 30 and 90 days
|
At admission, discharge and at readmission.
|
30 and 90 days
|
Change in C-reactive protein (CRP) blood biomarker
Time Frame: 30 and 90 days
|
At admission, discharge and at readmission.
|
30 and 90 days
|
Change in Eosinophils blood biomarker
Time Frame: 30 and 90 days
|
At admission, discharge and at readmission.
|
30 and 90 days
|
Change in Neutrophils blood biomarker
Time Frame: 30 and 90 days
|
At admission, discharge and at readmission.
|
30 and 90 days
|
Change in troponin blood biomarker
Time Frame: 30 and 90 days
|
At admission, discharge and at readmission.
|
30 and 90 days
|
Change in B-type Natriuretic Peptide (BNP) blood biomarker
Time Frame: 30 and 90 days
|
At admission, discharge and at readmission.
|
30 and 90 days
|
Change in procalcitonin blood biomarker
Time Frame: 30 and 90 days
|
At admission, discharge and at readmission.
|
30 and 90 days
|
Change in fibrinogen blood biomarker
Time Frame: 30 and 90 days
|
At admission, discharge and at readmission.
|
30 and 90 days
|
Change in sputum biomarkers
Time Frame: 30 and 90 days
|
This is used to assess bacteria species, load and resistance to antibiotics, and markers of inflammation such as IL-8.
|
30 and 90 days
|
Number of hospital admissions in the previous year.
Time Frame: 30 and 90 days
|
The investigators will record it to find the difference between patients who are and are not readmitted to the hospital within 30 and 90 days.
|
30 and 90 days
|
Number of exacerbations in the previous year.
Time Frame: 30 and 90 days
|
The investigators will record it to find the difference between patients who are and are not readmitted to the hospital within 30 and 90 days.
|
30 and 90 days
|
Use of long-term oxygen therapy (LTOT)
Time Frame: 30 and 90 days
|
The investigators will record it to find the difference between patients who are and are not readmitted to the hospital within 30 and 90 days.
|
30 and 90 days
|
Length of stay (LOS) in hospital
Time Frame: 30 and 90 days
|
The investigators will record it to find the difference between patients who are and are not readmitted to the hospital within 30 and 90 days.
|
30 and 90 days
|
Use of non-invasive ventilation (NIV)
Time Frame: 30 and 90 days
|
The investigators will record it to find the difference between patients who are and are not readmitted to the hospital within 30 and 90 days.
|
30 and 90 days
|
Previous admission to the ICU
Time Frame: 30 and 90 days
|
The investigators will record it to find the difference between patients who are and are not readmitted to the hospital within 30 and 90 days.
|
30 and 90 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrence
-
Portuguese Oncology Institute, CoimbraCompletedColorectal Cancer | Recurrence, Local NeoplasmPortugal
-
Chinese PLA General HospitalRecruitingHCC | Recurrence TumorChina
-
Paracelsus Medical UniversityHeinrich-Heine University, Duesseldorf; Poznan University of Medical Sciences; University Hospital of Ferrara and other collaboratorsCompletedToxicity | Local Neoplasm RecurrenceAustria
-
General Hospital GroeningeUniversitaire Ziekenhuizen KU Leuven; Jessa Hospital; University Hospital, Ghent and other collaboratorsNot yet recruiting
-
Dallas VA Medical CenterTerminatedSolid Tumors | Cancer RecurrenceUnited States
-
The University of Hong KongHealth and Medical Research FundNot yet recruitingCancer | Fear of Cancer Recurrence
-
German Centre for Assessment and Evaluation of...Not yet recruitingComplication | Continence | Potency | Biochemical RecurrenceGermany
-
The University of Hong KongNot yet recruitingCancer | Fear of Cancer Recurrence
-
RottapharmTerminatedHCV Recurrence After Liver Transplantation
-
The University of Hong KongHealth and Medical Research FundNot yet recruitingCancer | Fear of Cancer Recurrence | Psychooncology
Clinical Trials on Spirometry, Forced Oscillation Technique, Step-counter, sputum and blood samples
-
Council of Scientific and Industrial Research,...UnknownMetabolic Syndrome | Small Airway Disease | Early Adult Lung FunctionIndia
-
Imperial College LondonRoyal Brompton & Harefield NHS Foundation Trust; Action Medical Research; Masonic...Not yet recruiting
-
The Hospital for Sick ChildrenDalhousie UniversityCompletedAsthma | Obstructive Sleep Apnea | Food Allergy | Virus | WheezeCanada
-
University of NottinghamRecruiting
-
Imperial College LondonGlaxoSmithKlineWithdrawnHealthy Smokers | Healthy Non-smokers | Patients With Mild Asthma | Patints With COPD (GOLD II)United Kingdom